Quantcast
Last updated on April 16, 2014 at 4:43 EDT

Latest Bacillus Calmette-Guérin Stories

2012-01-09 23:01:00

Agreement Positions China as a Critical Player in the TB Vaccine Field ROCKVILLE, Md. and BEIJING, Jan. 10, 2012 /PRNewswire-USNewswire/ -- The global fight against the tuberculosis epidemic receives a boost today as Aeras and the China National Biotec Group (CNBG) announce that they have reached final agreement to jointly develop new tuberculosis (TB) vaccines. The agreement between the leading non-profit developer of TB vaccine candidates and the largest biotechnology...

2011-12-02 01:46:06

The World Health Organization estimates that one-third of the world's population is currently infected with the microbe that causes tuberculosis, Mycobacterium tuberculosis. The only vaccine, BCG, is largely ineffective; ways to enhance its effectiveness are desperately needed. A team of researchers – led by Peter Andersen, at Statens Serum Institut, Denmark, and JoAnne L. Flynn, at the University of Pittsburgh School of Medicine, Pittsburgh, – has now developed a vaccine that...

2011-11-07 16:17:35

The incidence of tuberculosis (TB) in the U.S. is reported as being on the decrease, however untreated infected people act as a reservoir for disease. Any pool of the world's population harboring this disease gives cause for concern, especially since the BCG vaccine is only 70-80% effective at best. New research published in BioMed Central's open access journal BMC Public Health, shows that in 2009 the number of cases of TB reported across America was much lower than that recorded in previous...

2011-10-12 15:47:00

SEATTLE, Oct. 12, 2011 /PRNewswire-USNewswire/ -- The Infectious Disease Research Institute (IDRI) has been awarded a two-year $300,000 grant from The Paul G. Allen Family Foundation to support IDRI's launch of a Phase 1 clinical trial of its new tuberculosis vaccine known as ID93/GLA-SE. The phase 1 trial will evaluate the safety and immunogenicity of ID93/GLA-SE in a group of healthy volunteers, and is expected to begin in early 2012. "We are thrilled to be supporting IDRI, a Seattle...

2011-09-08 10:14:31

(Ivanhoe Newswire) — A potential vaccine against tuberculosis (TB) has been found to completely eliminate TB bacteria from infected tissues in some mice. The vaccine was made from a strain of bacteria that are unable to avoid its host´s first-line immune response. Once this first-line defense has been activated, it triggers the more specific immune response that remembers the bacteria and protects against future infection. Tuberculosis, an infectious disease caused by...

2011-09-06 12:45:41

  An experimental vaccine composed of a genetically modified bacterium closely related to the bacterium that causes tuberculosis (TB) has been found to protect mice against TB infection, according to a study appearing online September 4 in the journal Nature Medicine. The research was funded in part by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health. TB, a respiratory disease that according to World Health Organization estimates...

2011-09-05 11:16:45

A potential vaccine against tuberculosis has been found to completely eliminate tuberculosis bacteria from infected tissues in some mice. The vaccine was created with a strain of bacteria that, due to the absence of a few genes, are unable to avoid its host's first-line immune response. Once this first-line defense has been activated, it triggers the more specific immune response that can protect against future infections. The research, by scientists at the Howard Hughes Medical Institute,...

2011-06-27 14:15:49

Generic drug reproduces mechanism that reversed diabetes in mice, Phase II trial now underway Promising results of the Phase I clinical trial of the generic drug BCG (bacillus Calmette-Guerin) to treat advanced type I diabetes were announced today at the American Diabetes Association scientific sessions in San Diego. A research team led by Denise Faustman, MD, PhD, director of the Massachusetts General Hospital (MGH) Immunobiology Laboratory is presenting two abstracts (No. 2240-PO and No....

2011-05-24 23:00:09

Clinical trials for a new bladder cancer therapy show promising interim results. Lead researcher Alvaro Morales says that the breakthrough using the drug Urocidin follows thirty years of his research in this important area. "I am optimistic about the results of the trial," says Dr. Morales, professor emeritus in the Department of Urology at Queen's University and director of the Queen's University Centre for Applied Urological Research. "Positive results in the next phase of trials will move...

2011-05-17 15:05:00

CHADDS FORD, Pa. and BELLEVILLE, Ontario, May 17, 2011 /PRNewswire/ -- Endo Pharmaceuticals and Bioniche Life Sciences today presented Phase III trial results for the intravesical formulation of Mycobacterial cell wall-DNA complex (MCC), known as Urocidin(TM), during a podium presentation at the 2011 American Urological Association annual meeting in Washington, D.C. The preliminary results from the interim analysis of this prospective trial indicate that Urocidin(TM) may provide an...


Latest Bacillus Calmette-Guérin Reference Libraries

45_255d6ba67dfe6f32b9c7c31f338bf912
2011-04-18 22:11:24

Mycobacterium bovis is a slow-growing, aerobic bacterium and the causative agent of tuberculosis in cattle. Similar to M. tuberculosis, M. bovis can jump the species barrier and cause tuberculosis in humans. It is estimated that M. bovis was responsible for more losses among farm animals than all other diseases combined in the first half of the 20th century. Infection happens after bacterium is ingested. It is generally transmitted to humans via infected milk. Actual human infections are...

More Articles (1 articles) »